EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase inhibitors (TKIs) have become a first-line therapy option for patients with stage IV NSCLC (4) due to their notable antitumor activity and extended progression-free survival (PFS) and overall survival (OS).